For research use only. Not for therapeutic Use.
Vernakalant(CAT: I004900), also known as RSD-1235, is an investigational mixed ion channel blocker. It is primarily studied for its potential use in the treatment of atrial fibrillation, a common heart rhythm disorder. Vernakalant exerts its effects by blocking multiple ion channels, including the potassium and sodium channels, which help to stabilize and restore normal electrical conduction in the heart. By restoring normal heart rhythm, vernakalant aims to reduce the symptoms and complications associated with atrial fibrillation.
| Catalog Number | I004900 |
| CAS Number | 794466-70-9 |
| Synonyms | 1-(2-(3,4-dimethoxyphenethoxy)cyclohexyl)pyrrolidin-3-ol |
| Molecular Formula | C20H31NO4 |
| Purity | ≥95% |
| Target | Potassium Channel |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol |
| InChI | InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1 |
| InChIKey | VBHQKCBVWWUUKN-KZNAEPCWSA-N |
| SMILES | COC1=C(OC)C=C(CCOC2CCCCC2N3CCC(O)C3)C=C1 |
| Reference | 1: van Hunnik A, Nasrallah H, Lau DH, Kuiper M, Verheule S, Schotten U. Vernakalant does not alter early repolarization or contractility in normal and electrically remodelled atria. Europace. 2017 Apr 25. doi: 10.1093/europace/eux025. [Epub ahead of print] PubMed PMID: 28449044.<br /> |
